Kimera Labs Inc. is a biotechnology company that develops perinatal exosome products for research and therapeutic purposes. Since 2012, Kimera Labs and Kimera Society have invested significant resources into exosome isolation and therapy protocols for the treatment of burns, orthopedics, COPD and inflammatory diseases.
Functioning within a 6,000 sq ft ISO:9001/13485 certified facility in Miramar, Florida, we feature ISO 5 GMP hoods, class 7 cleanrooms, in-house particle size and flow cytometry characterization of incoming and outgoing cell phenotypes and much more.
As a regenerative medicine focused biotechnology company, Kimera Labs develops therapies that heal from within. By providing regenerative cellular signals under the control of messenger and micro RNA, we believe it is possible to instantiate healing processes that can benefit patients of any age.
In 2004, my Oceanographer father and I were faced with an almost impossible decision. The chemotherapy we were using to treat his leukemia was no longer functional, and we were forced to choose an immunological approach, bone marrow stem cell transplantation (BMT), for which the rate of survival was 50%. We hesitated for so long that when we finally decided on BMT he was no longer eligible. I clearly remember meekly offering a well known program director at Massachusetts General Hospital a random paper on Copper supplementation for the treatment of AML. She politely thanked me and raised her hand in a negative response. After this encounter, and two years before his death, I enrolled in the Ph.D. program at the University of Miami. After a dual education in biochemistry and immunology I am today still trying to control disease and rejection using immunological approaches. One of the directions that showed early promise in chronic GVHD after BMT was the use of mesenchymal stromal cells to suppress rejection. My study of immunological manipulation, in concert with the understanding I have developed of what the 'paracrine effect' of cell communication really means, has led our company down a path that has resulted in multiple FDA IND applications in process, and our position as one of the most well respected groups in exosome science.
I am happy to contribute to the body of knowledge of exosome research that is truly leading us towards a thousand year life span. Feel free to ask us for our protein, mRNA, or miRNA research results that help us define the evolving science that is cellular signalling.
Duncan Ross Ph.D.
Kimera Labs is an FDA registered tissue bank located in Miramar Florida. Our amniotic fluid products fall under 361 tissue product regulation while the XoGlo exosome product is for topical use only.
The donor mother's serum in is each case is tested for the following viruses:
Further IND applications for tissue specific therapies are underway.